Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as Potential COVID-19 Therapeutics.

MLA

Wang, Xuanting, et al. “Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as Potential COVID-19 Therapeutics.” BioRxiv : The Preprint Server for Biology, July 2021. EBSCOhost, https://doi.org/10.1101/2021.07.21.453274.

APA

Wang, X., Sacramento, C. Q., Jockusch, S., Chaves, O. A., Tao, C., Fintelman-Rodrigues, N., Chien, M., Temerozo, J. R., Li, X., Kumar, S., Xie, W., Patel, D. J., Meyer, C., Garzia, A., Tuschl, T., Bozza, P. T., Russo, J. J., Souza, T. M. L., & Ju, J. (2021). Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as Potential COVID-19 Therapeutics. BioRxiv : The Preprint Server for Biology. https://doi.org/10.1101/2021.07.21.453274

Chicago

Wang, Xuanting, Carolina Q Sacramento, Steffen Jockusch, Otávio Augusto Chaves, Chuanjuan Tao, Natalia Fintelman-Rodrigues, Minchen Chien, et al. 2021. “Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as Potential COVID-19 Therapeutics.” BioRxiv : The Preprint Server for Biology, July. doi:10.1101/2021.07.21.453274.